🌐 EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

← Trials
🧪

Study to Assess Prevalence of the Folate Receptor Alpha (FRa) in Adult Female Participants With Ovarian Cancer in Intercontinental (InterCon) Countries

Recruitingn/aAges 18 Years - anyFemaleAbbVie
NCT07539844 on ClinicalTrials.gov ↗
💬

In plain words

What the trial is, and whether it could suit you

Epithelial ovarian cancer (OC), including fallopian tube and primary peritoneal cancer, is the deadliest gynecologic malignant neoplasm with a 5-year relative survival of approximately 50%. This study will evaluate the concordance in folate receptor alpha (FRa) immunohistochemistry (IHC) in adult female participants with ovarian cancer. Archived tissue biopsies will be tested for FRa and data from approximately 1,000 participants will be collected. This is a retrospective study and testing will be performed prospectively on archived samples. Participants' charts will be reviewed. No drug will be administered as a part of this study. The duration of the study will be approximately 1 Year. There is no additional burden for participants in this trial.

Sign in to get the eligibility rules as simple questions to take to your doctor.

Sign in
📋 Eligibility rules (as published)
Inclusion Criteria: * Surgical or biopsy samples (Formalin Fixed Paraffin Embedded \[FFPE\]) with tumoral High Grade Serous Ovarian Cancer (HGSOC) material allowing the sectioning of serial slides for all the analyses. * Archival specimens should not be older than 5 years in order to control quality of the samples. * Specimens containing a minimum of 100 viable tumor cells. Exclusion Criteria: * Surgical or biopsy samples (FFPE) with insufficient quantity or quality (sampled more than 5 years ago and/or with less 100 viable tumor cells per section). * Tissue obtained following treatment with Mirvetuximab soravtansine or any other FRa targeted therapy. * Tissue obtained through fine needle aspirations or liquid specimens, or ascites
💊

What it tests

  • Not listed
📍

Where

12 sites
Biomakers /ID# 280318
Buenos Aires, Argentina
Hospital Italiano de Buenos Aires /ID# 280315
Buenos Aires, Argentina
Instituto Alexander Fleming /ID# 281479
Ciudad Autonoma de Buenos Aire, Argentina
A.C. Camargo Cancer Center - Rua Professor Antonio Prudente /ID# 280407
São Paulo, Brazil
Brazil - Generic Institution /ID# 287000
São Paulo, Brazil
Toronto General Hospital-University Health Network /ID# 282521
Toronto, Canada
Fundacion Para La Investigacion Clinica Y Molecular Aplicada Del Cancer - Ficmac /ID# 282327
Bogotá, Colombia
Instituto Nacional De Cancerologia /ID# 282312
Bogota, Colombia

…and 4 more on ClinicalTrials.gov.

🤝 Taking part is your choice, and you can leave at any time. Only the trial team can confirm you are eligible — always decide together with your own doctor.
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy